Nurix Therapeutics, Inc.
NRIX Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$25.55
KIRA · Stoqly’s AI analyst, in plain words
- Nurix Therapeutics, Inc. had $84.0M of revenue in fiscal 2025, up 54.0% on the year before. Over five years, revenue changed +36.3% a year on average.
- Its operating margin was −340.2%, up 50.4 pts: of every 100 in sales, about −340 is left after running the business.
- Nurix Therapeutics, Inc. lost $264M in fiscal 2025.
- Free cash flow was −$263M in fiscal 2025, −313.7% of revenue.
Market cap
$3.0B
P/E
11.1x
Revenue
$84.0M
Net income
−$264M
Free cash flow
−$263M
Operating margin
−340.2%
Nurix Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+54.0%
Yes. Sales grew 54.0% last year.
Does it make a profit?
−314.9%
No. It lost money last year.
Does profit turn into cash?
−313.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
11.1x
One share costs 11.1 times its yearly profit per share.
What Nurix Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- November 30, 2025
- Latest annual report
- 10-K · Jan 28, 2026
- Legal name
- Nurix Therapeutics, Inc.
- CIK
- 0001549595
Nurix Therapeutics, Inc. · NRIX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $29.8M | $38.6M | $77.0M | $54.5M | $84.0M |
| Revenue growth | 66.9% | 29.8% | 99.3% | −29.1% | 54.0% |
| Operating margin | −396.3% | −476.0% | −201.4% | −390.5% | −340.2% |
| Net income | −$117M | −$180M | −$144M | −$194M | −$264M |
| Net margin | −393.9% | −466.9% | −187.0% | −354.9% | −314.9% |
| Diluted EPS | −$2.73 | −$3.71 | −$2.65 | −$2.88 | −$3.05 |
| Cash | |||||
| Cash from operations | −$84.4M | −$160M | −$81.4M | −$173M | −$249M |
| Capital expenditure | $5.7M | $12.2M | $8.4M | $9.3M | $14.0M |
| Free cash flow | −$90.0M | −$172M | −$89.8M | −$182M | −$263M |
| FCF margin | −302.6% | −445.4% | −116.6% | −333.4% | −313.7% |
| Share count change | 173.7% | 13.3% | 11.8% | 23.5% | 29.1% |
| Debt and strength | |||||
| Cash and short-term investments | $296M | $309M | $54.6M | $110M | $247M |
| Shareholders' equity | $342M | $304M | $200M | $527M | $539M |
| Current ratio | 4.7x | 4.5x | 3.4x | 6.5x | 7.0x |
| Returns and quality | |||||
| Return on equity | −37.1% | −55.8% | −57.1% | −53.2% | −49.6% |
| Return on tangible equity | −34.2% | −59.4% | −71.8% | −36.7% | −49.1% |
| Piotroski F-score | 2 | 2 | 3 | 3 | 3 |
| Altman Z'' | 2.9 | 0.6 | −2.7 | 3.3 | 1.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$5.2M
4 insiders
Of sales under plans
76%
$4.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Nurix Therapeutics, Inc. · NRIX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $25.55 a share, the company is worth $3.0B: 11.1 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001549595). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.